Arius Research Inc, is a biotechnology company that specializes in personalizing cancer therapy through the discovery and development of novel anticancer monoclonal antibodies (MAbs). It has built a proprietary technology platform, FunctionFIRST, which identifies MAbs in a rapid and cost-effective manner. The Company has assembled a growing pipeline of over 200 functional Mabs, which may be used for commercial collaborations, out-licensing or in-house development. The Company's long-term goal is to deliver personalized therapy by matching multiple antibodies to the distinct antigenic characteristics of each patient's tumor cells thereby increasing efficacy and avoiding side effects. The company has 20 employees.